CA3140637A1 - Antifungal agents, like ibrexafungerp for candida auris decolonization - Google Patents

Antifungal agents, like ibrexafungerp for candida auris decolonization Download PDF

Info

Publication number
CA3140637A1
CA3140637A1 CA3140637A CA3140637A CA3140637A1 CA 3140637 A1 CA3140637 A1 CA 3140637A1 CA 3140637 A CA3140637 A CA 3140637A CA 3140637 A CA3140637 A CA 3140637A CA 3140637 A1 CA3140637 A1 CA 3140637A1
Authority
CA
Canada
Prior art keywords
compound
candida auris
formula
pharmaceutically acceptable
mucosal tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3140637A
Other languages
English (en)
French (fr)
Inventor
David A. ANGULO GONZALEZ
Stephen Andrew BARAT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scynexis Inc
Original Assignee
Scynexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scynexis Inc filed Critical Scynexis Inc
Publication of CA3140637A1 publication Critical patent/CA3140637A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CA3140637A 2019-05-16 2020-05-12 Antifungal agents, like ibrexafungerp for candida auris decolonization Pending CA3140637A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962849019P 2019-05-16 2019-05-16
US62/849,019 2019-05-16
PCT/US2020/032547 WO2020232037A1 (en) 2019-05-16 2020-05-12 Antifungal agents, like ibrexafungerp for candida auris decolonization

Publications (1)

Publication Number Publication Date
CA3140637A1 true CA3140637A1 (en) 2020-11-19

Family

ID=70861571

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3140637A Pending CA3140637A1 (en) 2019-05-16 2020-05-12 Antifungal agents, like ibrexafungerp for candida auris decolonization

Country Status (14)

Country Link
US (1) US20220211684A1 (https=)
EP (1) EP3968986A1 (https=)
JP (2) JP7770191B2 (https=)
KR (1) KR20220009416A (https=)
CN (1) CN113905733A (https=)
AU (1) AU2020276595B2 (https=)
BR (1) BR112021022876A2 (https=)
CA (1) CA3140637A1 (https=)
EA (1) EA202193146A1 (https=)
IL (1) IL288165B1 (https=)
MA (1) MA55958A (https=)
MX (1) MX2021013899A (https=)
TW (2) TWI881977B (https=)
WO (1) WO2020232037A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250006380A (ko) 2023-07-03 2025-01-13 연세대학교 산학협력단 칸디다 아우리스에 대한 항진균제 스크리닝 방법 및 항진균용 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756472A (en) 1996-01-31 1998-05-26 Merck & Co., Inc. Antifungal agent obtained from hormonema
JP5245057B2 (ja) 2006-04-03 2013-07-24 メルク・シャープ・アンド・ドーム・コーポレーション 抗真菌剤
WO2010019204A1 (en) 2008-08-12 2010-02-18 Merck Sharp & Dohme Corp. Antifungal agents
KR101686075B1 (ko) * 2008-08-12 2016-12-13 싸이넥시스, 인크. 항균제
MA43825A (fr) * 2016-03-16 2021-04-07 Cidara Therapeutics Inc Schémas posologiques pour le traitement d'infections fongiques
MA49889A (fr) * 2017-04-10 2020-06-24 Scynexis Inc Agents antifongiques utilisés en association
AU2018269892A1 (en) * 2017-05-17 2019-11-28 T2 Biosystems, Inc. NMR methods and systems for the rapid detection of Candida species
KR102807716B1 (ko) * 2017-08-04 2025-05-13 싸이넥시스, 인크. 산성 pH에서 증진된 활성을 갖는 항진균제
US20220117948A1 (en) * 2019-01-30 2022-04-21 Scynexis, Inc. Triterpenoid antifungals for the treatment of fungal osteo-articular infections

Also Published As

Publication number Publication date
CN113905733A (zh) 2022-01-07
TW202110441A (zh) 2021-03-16
EA202193146A1 (ru) 2022-02-11
US20220211684A1 (en) 2022-07-07
MX2021013899A (es) 2022-02-10
IL288165B1 (en) 2026-01-01
KR20220009416A (ko) 2022-01-24
EP3968986A1 (en) 2022-03-23
AU2020276595A1 (en) 2021-12-09
AU2020276595B2 (en) 2025-12-04
TWI881977B (zh) 2025-05-01
WO2020232037A1 (en) 2020-11-19
JP2025118765A (ja) 2025-08-13
BR112021022876A2 (pt) 2022-04-12
JP2022532734A (ja) 2022-07-19
TW202602460A (zh) 2026-01-16
JP7770191B2 (ja) 2025-11-14
MA55958A (fr) 2022-03-23
IL288165A (en) 2022-01-01

Similar Documents

Publication Publication Date Title
US20150031640A1 (en) Antibacterial agents: combination of a rifamycin and a switch region inhibitor
AU2024227501A1 (en) Antifungal agents with enhanced activity in acidic pH
JP2025118765A (ja) カンジダ・アウリス（Ｃａｎｄｉｄａ ａｕｒｉｓ）脱コロニー化のためのイブレクサファンゲルプのような抗真菌剤
US20250248983A1 (en) Triterpenoid antifungals for the treatment of fungal osteo-articular infections
EA048874B1 (ru) Противогрибковые агенты для деколонизации candida auris
HK40067174A (zh) 用於消除耳念珠菌移生的如依贝瑞芬赫普的抗真菌剂
JP7581219B2 (ja) ニューモシスチス属種（Ｐｎｅｕｍｏｃｙｓｔｉｓ ｓｐｐ．）肺炎を治療又は予防するためのトリテルペノイド系抗真菌薬
HK40062374A (en) Triterpenoid antifungals for the treatment of fungal osteo-articular infections
HK40062374B (en) Triterpenoid antifungals for the treatment of fungal osteo-articular infections
HK40091926A (en) Antifungal agents with enhanced activity in acidic ph
EA051506B1 (ru) Тритерпеноидные фунгициды для лечения грибковых костно-суставных инфекций
HK40066679B (en) Triterpenoid antifungals for the treatment of pneumocystis spp. pneumonia
HK40066679A (en) Triterpenoid antifungals for the treatment of pneumocystis spp. pneumonia
HK40030410A (en) Antifungal agents with enhanced activity in acidic ph

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240508

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250506

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250508

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250508

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250903

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251121

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251121

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251121